{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T03:05:09Z","timestamp":1760151909055,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005039","name":"Leiden University Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.omton.2025.201018","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T15:30:40Z","timestamp":1752766240000},"page":"201018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["DNA-demethylation by DAC induces MAGE expression and MAGE-specific T cell reactivity against tumors but also healthy cell subsets"],"prefix":"10.1016","volume":"33","author":[{"given":"Marije A.J.","family":"de Rooij","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miranda H.","family":"Meeuwsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne K.","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis F.G.","family":"Remst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate S.","family":"Hagedoorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk M.","family":"van der Steen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Els M.E.","family":"Verdegaal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-2530","authenticated-orcid":false,"given":"Tassilo L.A.","family":"Wachsmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.H. Frederik","family":"Falkenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjam H.M.","family":"Heemskerk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2025.201018_bib1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.canlet.2017.03.029","article-title":"Oncogenic roles of DNA hypomethylation through the activation of cancer-germline genes","volume":"396","author":"Van Tongelen","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omton.2025.201018_bib2","first-page":"1766","article-title":"Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine","volume":"54","author":"Weber","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.201018_bib3","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/pros.20665","article-title":"Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor","volume":"67","author":"Dubovsky","year":"2007","journal-title":"Prostate"},{"key":"10.1016\/j.omton.2025.201018_bib4","doi-asserted-by":"crossref","first-page":"84359","DOI":"10.18632\/oncotarget.12711","article-title":"Inducible expression of cancer-testis antigens in human prostate cancer","volume":"7","author":"Heninger","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2025.201018_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108632","article-title":"Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma","volume":"112","author":"Shi","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.omton.2025.201018_bib6","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00262-011-1037-z","article-title":"MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing","volume":"60","author":"Bao","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2025.201018_bib7","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1007\/s13277-014-1764-9","article-title":"Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1","volume":"35","author":"Krishnadas","year":"2014","journal-title":"Tumour Biol."},{"key":"10.1016\/j.omton.2025.201018_bib8","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.4049\/jimmunol.1502024","article-title":"MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses","volume":"197","author":"Kunert","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2025.201018_bib9","first-page":"454","article-title":"Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes","volume":"9","author":"Zhang","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.omton.2025.201018_bib10","doi-asserted-by":"crossref","first-page":"9167","DOI":"10.1158\/0008-5472.CAN-04-1442","article-title":"Intratumor heterogeneity of cancer\/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine","volume":"64","author":"Sigalotti","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.201018_bib11","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.omton.2025.201018_bib12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.18632\/oncotarget.1782","article-title":"Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2025.201018_bib13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.omton.2025.201018_bib14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1053\/j.seminoncol.2005.07.024","article-title":"Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents","volume":"32","author":"Claus","year":"2005","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.omton.2025.201018_bib15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/ph5080875","article-title":"A Perspective on the Comparative Antileukemic Activity of 5-Aza-2'-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)","volume":"5","author":"Momparler","year":"2012","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.omton.2025.201018_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201018_bib17","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ccr.2011.12.029","article-title":"Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells","volume":"21","author":"Tsai","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2025.201018_bib18","doi-asserted-by":"crossref","first-page":"11797","DOI":"10.1073\/pnas.91.25.11797","article-title":"Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation","volume":"91","author":"Juttermann","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2025.201018_bib19","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2008-02-140038","article-title":"Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines","volume":"113","author":"Qin","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201018_bib20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/03602532.2018.1437446","article-title":"Effects of 5-Aza-2'-deoxycytidine (decitabine) on gene expression","volume":"50","author":"Seelan","year":"2018","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.omton.2025.201018_bib21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1124\/mol.65.1.18","article-title":"Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine","volume":"65","author":"Karpf","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.omton.2025.201018_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2022.11.007","article-title":"A library of cancer testis specific T cell receptors for T cell receptor gene therapy","volume":"28","author":"de Rooij","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2025.201018_bib23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1084\/jem.186.2.239","article-title":"Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells","volume":"186","author":"Kurts","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2025.201018_bib24","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1073\/pnas.1322420111","article-title":"Stretched cell cycle model for proliferating lymphocytes","volume":"111","author":"Dowling","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2025.201018_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.727441","article-title":"Cell Cycle Entry Control in Naive and Memory CD8(+) T Cells","volume":"9","author":"Lewis","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omton.2025.201018_bib26","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.omton.2025.201018_bib27","first-page":"671","article-title":"Severe Combined Immunodeficiency Disorders","volume":"35","author":"Chinn","year":"2015","journal-title":"Immunol. Allergy Clin."},{"key":"10.1016\/j.omton.2025.201018_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1158\/2326-6066.CIR-13-0126","article-title":"Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer","volume":"2","author":"Odunsi","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2025.201018_bib29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ctrv.2017.01.004","article-title":"Clinical and biological effects of demethylating agents on solid tumours - A systematic review","volume":"54","author":"Linnekamp","year":"2017","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.omton.2025.201018_bib30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00002371-199901000-00003","article-title":"Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR)","volume":"22","author":"Coral","year":"1999","journal-title":"J. Immunother."},{"key":"10.1016\/j.omton.2025.201018_bib31","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.1128\/MCB.19.11.7327","article-title":"DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter","volume":"19","author":"De Smet","year":"1999","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omton.2025.201018_bib32","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ymthe.2021.08.010","article-title":"A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy","volume":"30","author":"Meeuwsen","year":"2022","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925000876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925000876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:58:18Z","timestamp":1760147898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329925000876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2950329925000876"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2025.201018","relation":{},"ISSN":["2950-3299"],"issn-type":[{"type":"print","value":"2950-3299"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA-demethylation by DAC induces MAGE expression and MAGE-specific T cell reactivity against tumors but also healthy cell subsets","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2025.201018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201018"}}